This is an old revision of this page, as edited by Boghog (talk | contribs) at 06:09, 27 December 2024 (created drug stub). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 06:09, 27 December 2024 by Boghog (talk | contribs) (created drug stub)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound| Monoclonal antibody | |
|---|---|
| Type | Bi-specific T-cell engager |
| Source | Human |
| Target | CD20, SIRPα |
Amulirafusp alfa (IMM0306) is a cancer immunotherapy that targets CD20-positive B-cell malignancies. It is a fusion protein that combines a CD20 monoclonal antibody with the CD47 binding domain of SIRPα, allowing it to simultaneously engage both CD20 and CD47 on cancer cells. Amulirafusp alfa has a dual mechanism of action that enhances both macrophage-mediated phagocytosis and natural killer cell activation.
References
- Yang J, Song Y, Zhou K, Li Z, Zhang M, Jing H, Wang Z, Yu L, Meng W, Lu Q, Tian W, Shi Y (December 2024). "Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study". Journal of Hematology & Oncology. 17 (1): 123. doi:10.1186/s13045-024-01646-2. PMC 11657391. PMID 39696680.
- Yang J, Li Z, Zhang M, Zhou K, Li Y, Yang Y, Wang Z, Yu L, Zhang J, Huang H, Cheng Y (September 2024). "839P Preliminary results from a phase II study of amulirafusp alfa (IMM0306) in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma". Annals of Oncology. 35: S610. doi:10.1016/j.annonc.2024.08.890.
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |